surmount-1 tirzepatide trial obesity without diabetes With respect to the SURMOUNT-MAINTAIN trial, which statement is false? 1. In SURMOUNT-MAINTAIN, the most common adverse events with were gastrointestinal events 2. In those patients who continued on placebo in Improved health‐related quality of life

Translational studies have supported a role for GLP-1RA-mediated slowing of gastric emptying in very early improvements in glycemia [16], but such studies have not been completed with tirzepatide

Those on the drug were less likely to die of cardiovascular causes or have their heart failure condition worsen compared with people taking the placebo

Open, honest and doesnt want to bandaid the problem

Some health insurers in the US will cover the cost, but others will not for example the government-funded Medicare programme for over-65s does not cover weight-loss medications

This dual-incretin mechanism is the defining feature of Tirzepatide research